Jeffrey Hong, MD
Ophthalmology · Pasadena, CANPI 1922049055
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,825 of the $8,551 with a category attached, or 79.8%. Alcon accounts for 80.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,888 and has fallen 60.6% since, to $1,925 in 2024.
Across 27 payments — averaging $316.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- Sight Sciences, Inc.$446
- Maculogix, Inc.$300
- Bausch & Lomb, A Division Of Bausch Health US, LLC$249
- Eyepoint US, Inc.$173
- Ivantis, Inc$154
- plus $365 from 8 others
What the payments were for
- Speaking & faculty fees$6,82580%
- Travel & lodging$120%
- Food & beverage$1,69420%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $6,864 |
| Sight Sciences, Inc. | 4 | $446 |
| Maculogix, Inc. | 1 | $300 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $249 |
| Eyepoint US, Inc. | 2 | $173 |
| Ivantis, Inc | 1 | $154 |
| Bausch & Lomb Americas Inc. | 1 | $124 |
| Carl Zeiss Meditec, Inc. | 1 | $57 |
| Glaukos Corporation | 1 | $52 |
| Novo Nordisk | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $35 |
| Biotissue Holdings Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$1,925
- OMNI(R) SURGICAL SYSTEM (US)$424
- AdaptDx$300
- Hydrus$154
- AcrySof IQ VIVITY IOL$139
- ENVISTA TORIC$124
- DEXYCU$114
How this compares
$8,551 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 14 | $3,431 |
| Brimonidine Tartrate | 11 | $2,837 |
| Prednisolone Acetate | 37 | $794 |
| Ketorolac Tromethamine | 33 | $436 |
| Doxycycline Hyclate | 17 | $333 |
| Ciprofloxacin Hcl | 21 | $158 |
| Latanoprost | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pasadena
- Srinivas SaddaPasadena$1M
- Michael IpPasadena$181K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.